Pancreatic Juice Diagnosis From Duodenum

Status Completed

Clinical Trial Summary

Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.

Clinical Trial Description

Pancreatic cancer (PC) is the most lethal of all major cancers with a five year survival rate of 5 %. While stage I and II tumors leads to an improvement in survival, almost all PCs are currently diagnosed at more advanced non-resectable stages since minimally invasive technique which is capable of screening early-stage PC does not exist. Serum CA19-9 is not recommended as a screening technique because of its low sensitivity and specificity. Imaging modalities such as MRI, CT, EUS and ERCP are more accurate but are not appropriate screening tools due to their high cost, discomfort and complications. Therefore, there is a strong demand for a screening tool with high sensitivity and specificity which is highly acceptable for the patient.

The investigators would like to standardize the detection method of pancreatic cancer that uses the duodenal juice as an optional endoscopic diagnosis. It's a very useful chance to collect pancreatic juice from duodenum, it is called "duodenal juice" ,if we collect them without additional invasion. The investigators would like to collect duodenal juice during undergoing upper gastrointestinal endoscopy and analyze the pancreatic tumor markers in duodenal juice. A definite diagnosis of the patient is made with histology, cytology or imaging diagnosis and the result of each definite diagnosis is correlated to the each marker analyzing result of duodenal juice. Therefore this study can be positioned as a feasibility study to confirm clinical performance. ;

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01699698
Study type	Interventional
Source	Olympus Corporation
Contact
Status	Completed
Phase	N/A
Start date	October 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05305001` - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Completed	`NCT01959672` - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer	Phase 2
Recruiting	`NCT03673423` - Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
Terminated	`NCT02495896` - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05351983` - Patient-derived Organoids Drug Screen in Pancreatic Cancer	N/A
Not yet recruiting	`NCT06026943` - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer	N/A
Completed	`NCT03054987` - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction	N/A
Terminated	`NCT02345460` - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study	Phase 2
Recruiting	`NCT02072616` - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.	Phase 3
Completed	`NCT02174887` - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer	Phase 1
Recruiting	`NCT03703063` - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer	Phase 1
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A
Recruiting	`NCT03073785` - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer	Phase 2
Completed	`NCT03665441` - Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC	Phase 3
Recruiting	`NCT04627246` - Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer	Phase 1
Not yet recruiting	`NCT06217666` - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)	Phase 1
Recruiting	`NCT05585320` - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04119362` - PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Completed	`NCT03105921` - Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma	N/A